Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/HPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss the pathology of Sjögren's disease and potential treatment targets, as well as the clinical criteria and biomarkers used to diagnose the disease and aid in patient classification. Upon completion of this activity, participants should be better able to: Recognize the burden of disease, impact on quality of life, and unmet needs experienced by patients with Sjögren's disease; Describe the pathology of Sjögren's disease and potential treatment targets; Apply clinical criteria, guidelines, and biomarkers to diagnose Sjögren's disease and aid in patient classification; and Identify patients who may derive benefit from novel therapeutic options for Sjögren's disease using clinical trial data and shared decision-making.

Go online to PeerView.com/CYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation. You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options. Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction. Upon completion of this activity, participants should be better able to: Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC; Treat IBS/CIC in accordance with current evidence and guidelines, recog

Go online to PeerView.com/QSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Rett syndrome discusses the diagnosis and management of this rare disease, as well as the latest data on emerging treatment options. A 3D animation offers an overview of MECP2 mutation, hypothesized to be a major contributor to the CNS manifestations of Rett syndrome. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in infants demonstrating subtle signs and symptoms; Implement consensus recommendations on the age-specific management of patients with Rett syndrome; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of emerging pharmacologic treatment options to consider implementing these novel therapies when they become available.

Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate pati

Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients wit

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the

Go online to PeerView.com/ZXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease. At a recent live PeerView MasterClass & Practicum, a panel of PN experts offered evidence-based, practical guidance on current diagnostic and treatment strategies and the latest clinical data regarding novel therapies. The discussion was enhanced by a 3D animation depicting PN pathophysiology and patient videos providing perspectives on the burdens of disease and treatment experience. Upon completion of this activity, participants should be better able to: Recognize how the signs and symptoms of pr

Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaborat

Go online to PeerView.com/QYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in about 50% of patients with asthma and has emerged as a unifying feature of classically defined allergic diseases and a range of other inflammatory diseases. In this activity, an expert explains the advances in understanding of the pathogenesis of asthma and the targeted treatments that have been developed as a result. You will hear expert insights into the use of available and emerging biologic therapies, including how to identify children and adults who may be eligible for these therapies. Upon completion of this activity, participants should be better able to: Identify patients who would likely benefit from targeted therap

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatm

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individuali

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, d

Go online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19; Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures; and Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team.

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a c

Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel m

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don’t miss this exciting, informative learning opportunity! Up

Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.